Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Net: 2010-2025

Historic Receivables - Net for Arrowhead Pharmaceuticals (ARWR) over the last 8 years, with Sep 2025 value amounting to $6.8 million.

  • Arrowhead Pharmaceuticals' Receivables - Net was N/A to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year change of. This contributed to the annual value of $6.8 million for FY2025, which is N/A change from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Receivables - Net of $6.8 million as of Q3 2025, which was down 29.64% from $9.7 million recorded in Q2 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Receivables - Net peaked at $70.0 million during Q1 2023, and registered a low of $150,000 during Q4 2021.
  • Over the past 3 years, Arrowhead Pharmaceuticals' median Receivables - Net value was $4.7 million (recorded in 2024), while the average stood at $15.5 million.
  • Its Receivables - Net has fluctuated over the past 5 years, first crashed by 98.33% in 2021, then skyrocketed by 26,278.67% in 2022.
  • Arrowhead Pharmaceuticals' Receivables - Net (Quarterly) stood at $150,000 in 2021, then spiked by 26,278.67% to $39.6 million in 2022, then surged by 543.93% to $1.5 million in 2023, then reached $2.5 million in 2024, then reached $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $9.7 million for Q2 2025, and $2.4 million during Q1 2025.